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INTRODUCTION
Staphylococci are cause of many nosocomial and community acquired infections with high rates of morbidity and mortality all over the world. Antimicrobial resistance in Staphylococcus aureus, especially methicillin-resistant S.aureus (MRSA) isolates remain a major problem all over the world. 1, 2 Fusidic acid is a narrow-spectrum antibiotic derived from Fusidium coccineum used in S.aureus infections treatment for 40 years. Fusidic acid shows antibacterial activity by inhibiting bacterial protein synthesis. It is effective especially for methicillin-resistant staphylococci, particularly against many gram-positive aerobic and anaerobic bacteria. The basic indications for fusidic acid are systemic treatment of staphylococcal infections, MRSA infection and colonization and topical treatment of skin infections in atopic dermatitis. Studies have showed that fusidic acid may be a good alternative in S.aureus infections including nosocomial infections that pose difficulties in treatment. 3 In present study, in-vitro susceptibilities of a variety of staphylococcal strains isolated from clinical specimens to fusidic acid were investigated.
MATERIALS AND METHODS
The seventy-seven coagulase negative staphylococci (CNS) and 37 Staphylococcus aureus strains isolated from various clinical specimens that had been sent to Infectious Diseases and Clinical Microbiology laboratory in Kırıkkale University Hospital had been included in this study. The samples were inoculated in 5% blood agar medium and incubated at 37°C for 18-24 hours. Staphylococci were identified by gram stain, catalase and coagulase tests. Methicillin resistance was determined by incubation of oxacillin disk (1 μg) on Mueller-Hinton agar medium at 35°C for 24 hours. Oxacillin inhibition zone diameter >13 mm strains were evaluated as susceptible, <10 mm the strains were resistant. Antimicrobial susceptibility testing was performed by Kirby-Bauer disc diffusion method in accordance with the recommendations of "Clinical and Laboratory Standards Institute (CLSI)". 4 Susceptibility of fusidic acid was evaluated in accordance with the standards proposed by France of Microbiology and Antibiogram Committee; zone diameter was >22 mm considered as susceptible, 15-21 mm as intermediate, <15 mm as resistance. 5 In present study, the control strain of S.aureus ATCC 29213 standard strain was used.
RESULTS
The seventy-seven CNS and 37 S.aureus strains were included in this study. The seventy-four percent isolate of CNS's were defined as MS-CNS, 26% isolate of CNS's were defined as MR-CNS. While 40% of MR-CNS was resistant to fusidic acid and fusidic acid resistance was found to be 24% in MS-CNS.
Fusidic acid resistance was detected to be 13% in MSSA, while fusidic acid resistance was detected to be 14% in MRSA (Table 1) .
DISCUSSION
Fusidic acid is a steroid-like structured antibiotic isolated from fungi called Fusidium coccineum in 1962 and the only member of fusidan class used in the clinic. Fusidic acid shows antimicrobial effects mainly by inhibiting protein synthesis as a result of interfering elongation factor G. Because of this specific mechanism, it has been reported that it has very low probability of cross-resistance action with other groups of antibiotics. 6 Fusidic acid susceptibility is high against both methicillin-resistant, and methicillin-sensitive Staphylococcus strains as in-vitro. Therefore, these properties make it an important antibiotic in the per oral treatment of mild and moderate staphylococcal infections caused by methicillinresistant strains. 3, 6 It is obvious that efficiency of orally given fusidic acid is unreliable in cases of endocarditis, sepsis, pneumonia. Even if fusidic acid is detected to be sensitive in-vitro, glycopeptide drugs are to be preferred in MRSA sepsis or endocarditis. Fusidic acid is a drug that is used in mild to moderate uncomplicated infections, however severe infections can be treated by oral route as in combination with other antibiotics. 6 In our country several studies have been done about fusidic acid resistance related to staphylococci.
In a study carried out with 144 MSSA isolates and 71 MRSA isolates, Baysal et al. 7 have reported that 4 (3%) MSSA isolates and 8 (11%) MRSA isolates were resistant to fusidic acid. In a multi-center study, Altun et al. 8 detected fusidic acid resistance as 3% in total 202 MRSA isolates (Table 2 ). In a comprehensive study with 1,080 staphylococci strains isolated from wound, Ozcan et al.9 detected MR-CNS strains were the most fusidic acid-resistant strains and resistance rate as 30%. In same study resistance of MSSA strains was quite low (3%). In a study of Ulug et al. 10 resistance to fusidic acid has been found as 4.3% in methicillin-sensitive S.aureus strains, 16.7% in methicillin-resistant S.aureus strains, 0% in methicillin-sensitive coagulase-negative staphylococci, 36% in methicillin-resistant coagulase-negative staphylococci, however in none of the strains vancomycin, and teicoplanin resistance have been observed.
The presence of high sensitivity ratios of Staphylococcus strains to fusidic acid, suggested that this drug may be a viable option in the treatment of staphylococcal chronic osteomyelitis.
In a comprehensive study with 1,152 S.aureus strains in nine hospitals of Ireland, methicillin susceptibility has been found as 85% and fusidic acid susceptibility has been found as 96%. 11 Coombs et al. have applied alone and combined therapy to 20 patient who had acute orthopedic infection with CNS and they have received successful results in all patients. 12 In recent years, some overseas studies have shown that fusidic acid resistance has increased compared to previous years. In a study conducted by Mc Laws et al. 13 S.epidermidis strains obtained from clinical isolates have been found as highly resistant to fusidic acid. Fusidic acid resistance in community-acquired S.aureus strains has been found as 88.9% in a study by Katopodis et our study, it was detected that fusidic acid susceptibility of S.aureus strains was higher than the susceptibility of coagulase-negative staphylococci. Fusidic acid remains as an alternative option in the treatment of staphylococcal infections.
In conclusion, the increase of inappropriate antibiotic use causes increase of multiple-resistant bacterial infections. On the other hand, although being in use for many years, because of low resistance rates to fusidic acid, it is seen as a good option for the treatment of MRSA and MSSA infections. Because of the high efficiency in MS-CNS, MR-CNS, MRSA, MSSA infections; fusidic acid may be a preferred option in the treatment of uncomplicated mild to moderate infections.
